Headlands Technologies LLC Buys 23,074 Shares of Xenon Pharmaceuticals Inc. $XENE

Headlands Technologies LLC boosted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 377.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,194 shares of the biopharmaceutical company’s stock after acquiring an additional 23,074 shares during the quarter. Headlands Technologies LLC’s holdings in Xenon Pharmaceuticals were worth $1,762,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth about $454,057,000. Avoro Capital Advisors LLC raised its stake in shares of Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of Xenon Pharmaceuticals during the second quarter worth approximately $252,673,000. Janus Henderson Group PLC increased its holdings in shares of Xenon Pharmaceuticals by 2.3% in the first quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock worth $242,858,000 after buying an additional 91,948 shares during the period. Finally, Wellington Management Group LLP increased its stake in Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insiders Place Their Bets

In other news, Director Steven Gannon sold 10,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company’s stock, valued at $119,792.20. This represents a 84.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 12,512 shares of company stock valued at $774,088. Corporate insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $60.22 on Tuesday. The stock has a market cap of $5.82 billion, a price-to-earnings ratio of -12.70 and a beta of 0.62. The firm’s 50-day moving average is $63.29 and its 200 day moving average is $56.61. Xenon Pharmaceuticals Inc. has a 1 year low of $35.60 and a 1 year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter in the prior year, the company posted ($1.07) EPS. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on XENE shares. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Needham & Company LLC reduced their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wells Fargo & Company reissued an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Royal Bank Of Canada cut their price objective on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $77.13.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.